Puma's Neratinib Gets CHMP Turnaround But Slow EU Uptake Expected

13:03 EDT 27 Jun 2018 | SCRIP

Puma Biotech has proven to be the cat with nine lives after its HER2+ breast cancer treatment neratinib received a...

Original Article: Puma's Neratinib Gets CHMP Turnaround But Slow EU Uptake Expected

More From BioPortfolio on "Puma's Neratinib Gets CHMP Turnaround But Slow EU Uptake Expected"